Posted 13th March 2018 by Jane Williams
The pharmaceutical research industry is suffering from a lack of innovation, yet we see an exponential increase in new science and technologies. Open innovation, in the truest meaning, is a disruptive model that will greatly increase our joint chances of translating new research into treatments, but we need new ways of sharing and participating in collaborative drug research. Blockchain technologies can provide the digital infrastructure that allows trusted and secure transactions of research assets. Applying smart contracts on top of such infrastructure will further increase the speed of the life science ecosystem allowing exploration, co-creation, and transaction of research assets to happen in an unprecedented manner. In fact, we can’t afford to object to such a marriage between pharma open innovation and blockchain technologies.
Posted 31st January 2018 by Jane Williams
This article was originally published on the Surrey CoDE blog in January 2018, and is published here with permission.